JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Inspire Medical Systems (NYSE:INSP) Stock

Key Points

• JPMorgan raised Inspire Medical Systems’ price target to $65 from $60 but maintained a neutral rating, implying about 5.1% upside from the prior close. Analysts overall rate the stock “Hold,” with an average target of $71.24.
• INSP shares fell 8% to $61.85, despite the company beating quarterly estimates with EPS of $0.14 versus $0.09 expected and revenue of $206.7 million versus $204.3 million expected.
• The earnings beat was offset by ongoing pressure: quarterly revenue declined 7.9% year over year and EPS fell from $0.38 to $0.14, while management expects only low-single-digit revenue growth in 2027.

Inspire Medical Systems (NYSE:INSP - Get Free Report) had its target price hoisted by JPMorgan Chase & Co. from $60.00 to $65.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage currently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price would suggest a potential upside of 5.09% from the stock's previous close.

INSP has been the topic of a number of other research reports. Royal Bank Of Canada upped their target price on shares of Inspire Medical Systems from $60.00 to $75.00 and gave the company a "sector perform" rating in a research report on Thursday, October 1st. Robert W. Baird lifted their price objective on Inspire Medical Systems from $73.00 to $77.00 and gave the company a "neutral" rating in a research note on Tuesday. Evercore set a $54.00 price objective on Inspire Medical Systems in a report on Tuesday, August 4th. Stifel Nicolaus increased their target price on Inspire Medical Systems from $75.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, September 11th. Finally, Piper Sandler raised their target price on Inspire Medical Systems from $60.00 to $70.00 and gave the company a "neutral" rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $71.24.

Inspire Medical Systems Stock Down 8.0%

NYSE:INSP traded down $5.36 on Tuesday, reaching $61.85. The company's stock had a trading volume of 562,875 shares, compared to its average volume of 1,043,012. Inspire Medical Systems has a 12-month low of $38.91 and a 12-month high of $147.03. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of 13.41, a price-to-earnings-growth ratio of 5.37 and a beta of 0.73. The stock has a 50 day moving average price of $68.69 and a 200 day moving average price of $58.82.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last announced its quarterly earnings results on Monday, November 2nd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.09 by $0.05. The business had revenue of $206.69 million for the quarter, compared to analyst estimates of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The company's quarterly revenue was down 7.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.38 EPS. Equities research analysts expect that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Activity at Inspire Medical Systems

In other Inspire Medical Systems news, insider Jason Kelly sold 963 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $59.55, for a total value of $57,346.65. Following the completion of the transaction, the insider owned 18,985 shares in the company, valued at $1,130,556.75. The trade was a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 2.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of INSP. Oregon Public Employees Retirement Fund grew its holdings in Inspire Medical Systems by 8.4% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 6,462 shares of the company's stock worth $448,000 after acquiring an additional 500 shares in the last quarter. ProShare Advisors LLC acquired a new stake in shares of Inspire Medical Systems in the 3rd quarter valued at $276,000. Vise Technologies Inc. acquired a new stake in shares of Inspire Medical Systems in the 3rd quarter valued at $252,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Inspire Medical Systems during the 3rd quarter worth $312,000. Finally, Pinnacle Wealth Planning Services Inc. lifted its position in shares of Inspire Medical Systems by 19.8% during the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 1,172 shares of the company's stock worth $81,000 after purchasing an additional 194 shares during the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter adjusted EPS of $0.14, above the $0.09 consensus estimate, while revenue of approximately $206.7 million also exceeded expectations of $204.3 million. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Robert W. Baird raised its price target to $77 from $73, while maintaining a neutral rating, implying substantial potential upside based on the current share price. Robert W. Baird Inspire Analyst Ratings
• Positive Sentiment: Piper Sandler increased its price target to $70 from $60 and kept a neutral rating, reflecting improved expectations despite continued uncertainty. Piper Sandler Inspire Analyst Ratings
• Neutral Sentiment: Management expects fiscal 2026 revenue of $850 million to $860 million and EPS of $1.20 to $1.40. The ranges broadly bracket analyst expectations, offering limited evidence of a meaningful upward revision.
• Neutral Sentiment: On the earnings call, Inspire projected low-single-digit revenue growth in 2027 as reimbursement and coding conditions stabilize. Stabilization is encouraging, but the growth outlook remains modest. Inspire Projects Low Single-Digit 2027 Revenue Growth
• Negative Sentiment: Third-quarter revenue declined 7.9% year over year and EPS fell from $0.38 to $0.14, highlighting ongoing operating pressure despite the quarterly consensus beat.
• Negative Sentiment: Barclays cut its price target to $62 from $65 and assigned an underweight rating, leaving little implied upside and reinforcing investor concerns about the company’s near-term growth profile. Barclays Inspire Analyst Ratings

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company's primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.